


PERSONAL INFORMATION

Federica Martorana

 Center of Experimental Oncology and Haematology
 Policlinico Universitario Vittorio Emanuele
 Via Santa Sofia, 78
 95100 Catania, Italy

 +39 347-7583391

 fede.marto.fm@gmail.com

Female | 10.01.1990 | Italian

CURRENT POSITION

PhD Student
 Department of Clinical and Experimental Medicine,
 University of Catania

EDUCATION AND TRAINING

- 11.2015-10.2020 **University of Messina, Medical Oncology Specialty**
 Final mark 50/50 cum laude (full marks with honors)
- 11.2019-10.2020 **New Drug Development Unit at the Oncology Instituto of Italian Switzerland (CH)**
 Clinical Research Fellowship
- 2008-2015 **University of Catania, School of Medicine**
 Final mark 110/110 cum laude (full marks with honors)
- 2003-2008 **Maturità classica (Humanities)**
 Lyceum "M. Cutelli", Catania
 Final mark 98/100

PERSONAL SKILLS

Mother tongue(s) Italian

Other language(s)

	UNDERSTANDING		SPEAKING		WRITING
	Listening	Reading	Spoken interaction	Spoken production	
English	C1	C2	C1	C1	C1

IELTS overall band score 8.0/9.0

ADDITIONAL INFORMATION

Abstracts

Martorana F, Cordio S, Bordonaro R, Vigneri P, Novello G, Aiello MA, Martines C, Soto Parra HJ. *Efficacy of Mitomycin C plus a Fluoropyrimidine in pretreated patients with metastatic colorectal cancer eligible for Regorafenib: results of a retrospective study*. Journal of Clinical Oncology (2015) 33: 15_suppl.

Motta L., Motta G., Banna G., **Martorana F**, Longhitano C., Inzerilli N., ...& Vigneri P. *EGFR mutational status in determining choice of TKIs or standard chemotherapy for patients with advanced non-small cell lung cancer*. Annals of Oncology (2017) 28: 6_suppl.

Cinausero M., Galli G., Basile D., **Martorana F**, De Santo I., Perroud H. A., ...& Sant M. *Prognostic value of the interval between the last neoadjuvant chemotherapy (CT) administration and breast surgery: Preliminary data of the NeoBracer international observational study*. Journal of Clinical Oncology (2018) 36: 15_suppl.

Colombo I, Genta S, **Martorana F**, Guidi M, Samartzis ESP, Brandt S, Gaggetta s, Moser L, Pascale MR, Terror T, Sessa c, Stathis A. 568P Phase I dose-escalation study of the dual PI3K/mTORC1/2 inhibitor Gedatolisib (PF-05212384) in combination with paclitaxel (P) and carboplatin (C) in patients (pts) with advanced solid tumours. Ann Oncol. 2020. 31 (S487).

Publications Vigneri P, **Martorana F**, Manzella L e Stella S. *Biomarkers and prognostic factors for malignant pleural mesothelioma*. Future Oncology (2015) 11.24s: 29-33.

Martorana F, Vigneri P, Cordio S. S., Martinez C., Novello G., Aiello M. M., ... & Soto Parra, H. J. *Efficacy of A Fluoropyrimidine plus Mitomycin C in Pretreated Patients with Metastatic Colorectal Cancer Eligible for Regorafenib: A Retrospective Study*. Aims Medical Science (2017), 4(4): 456-464.

Gerratana L., Basile D., Buono G., De Placido S., Giuliano M., Minichillo S., Coinu A., **F. Martorana**, I. De Santo, L. Del Mastro, ... & De Laurentiis, M. *Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype*. Cancer Treatment Reviews (2018) 68: 102-110.

Manzella L., Massimino M., Stella S., Tirrò E., Pennisi M.S., **Martorana F**, Motta G., Vitale S.R., ...& Vigneri P. *Activation of the IGF Axis in Thyroid Cancer: Implications for Tumorigenesis and Treatment*. Int J Mol Sci (2019) 2;20 (13);

Tirrò E., **Martorana F**, Romano C. Vitale S. R., Motta G., ...& Paolo Vigneri. *Molecular alterations in thyroid cancer: from bench to clinical practice*. Genes (2019) 10 (9); 709.

Martorana F, Vigneri P, Manzella L, Tirrò E, Soto Parra HJ. Delayed use of eribulin in a heavily pretreated liposarcoma patient, previously misdiagnosed as leiomyosarcoma. Fut Oncol. 2020; 16(1s): 9-13.

Martorana F, Genta S, Colombo I, Stathis A. Advances in drug development in oncology and opportunities from phase I trials. Swiss Cancer Bulletin. 2020; 2:127-134.

Milluzzo A, Vigneri P, **Martorana F**, Vigneri R, Sciacca L. Type 2 diabetes and cancer: problems and suggestions for best patient management. Explor Med. 2020; 1: 184-204.

Strazzanti A., **Martorana F**, Intagliata E., Lanzafame K., Pavone G., Sergi M., Gangi S., Manzella L., Basile F., Trovato C. Implications of Antidepressants Use in Breast Cancer: A Brief Review. Surg Gastroenterol Oncol. 2020;25(5):229-235.

Tirrò E., Massimino M., Romano C., **Martorana F**, Pennisi M.S., Stella S., Pavone G., Di Gregorio S., Puma A., Tomarchio C., Vitale S.R., Manzella L., Vigneri P. .Prognostic and Therapeutic Roles of the Insulin Growth Factor System in Glioblastoma. Front. Oncol. 2020; 10.

Courses July 16-21, 2015: ESO-ESMO Medical Students Course on Medical Oncology, Valencia, Spain

October 20-21, 2017: Vital Talk, Linguaglossa, Italy.

April 11-13, 2018: Corso di perfezionamento in Genetica Oncologica. Università degli Studi di Pisa.

May 03-05, 2018: ESMO Preceptorship in Immuno-Oncology. Lugano.

October 11-12 2019: ESMO Preceptorship on Breast Cancer. Lisbona.

Membership European Society of Medical Oncology (ESMO) - Member in Training since 2015.

Associazione Italiana di Oncologia Medica (AIOM) - Socio effettivo dal 2016.

Certifications

November 24, 2019: Certificate of Completion of International Conference on Harmonisation/Good Clinical Practice (ICH/GCP) Training.

October 13, 2018: IELTS International English Language Testing System, Overall Band 8.0/9.0 (C1)

Catania, 03.03.2021